Detalles de la búsqueda
1.
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Breast Cancer Res Treat
; 170(3): 547-557, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29675680
2.
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
Clin Breast Cancer
; 13(4): 239-246.e1, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23829890
3.
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.
J Clin Oncol
; 31(33): 4179-87, 2013 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24002495
Resultados
1 -
3
de 3
1
Próxima >
>>